| Identification | Back Directory | [Name]
HMN 176 | [CAS]
173529-10-7 | [Synonyms]
HMN 176
HMN-176
CS-2239
HMN 176; HMN176
Benzenesulfonamide, 4-methoxy-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-
(NE)-N-[(6E)-6-[2-(1-hydroxypyridin-4-ylidene)ethylidene]cyclohexa-2,4-dien-1-ylidene]-4-methoxybenzenesulfonamide | [Molecular Formula]
C20H18N2O4S | [MOL File]
173529-10-7.mol | [Molecular Weight]
382.43 |
| Chemical Properties | Back Directory | [Boiling point ]
632.9±65.0 °C(Predicted) | [density ]
1.24±0.1 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO : ≥ 30 mg/mL (78.45 mM) | [form ]
Solid | [pka]
8.07±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
HMN-176?is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization.? | [in vivo]
After p.o. of HMN-214 to male rats, the prodrug is not detected in the plasma, while plasma levels of HMN-176 peaks at 2 h and gradually decreases thereafter[3]. | [References]
[1] DiMaio MA, et al. The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation. Mol Cancer Ther. 2009 Mar;8(3):592-601. DOI:10.1158/1535-7163.MCT-08-0876
[2] Medina-Gundrum L, et al. Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression. Invest New Drugs. 2005 Jan;23(1):3-9. DOI:10.1023/B:DRUG.0000047100.64540.f6
[3] Takagi M, et al. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Invest New Drugs. 2003 Nov;21(4):387-99. DOI:10.1023/a:1026282716250
[4] Tanaka H, et al. HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Cancer Res. 2003 Oct 15;63(20):6942-7. PMID:14583495
[5] Garland LL, et al. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res. 2006 Sep 1;12(17):5182-9. DOI:10.1158/1078-0432.CCR-06-0214 |
|
|